JP2003171310A - Skin barrier function-reinforcing agent - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To obtain a skin barrier function-reinforcing agent which can reinforce the barrier functions of the skin and can prevent and improve lesions caused by various stresses added from ambient environments to the skin, and to provide a skin care preparation. <P>SOLUTION: This skin barrier function-reinforcing agent is characterized by containing one or more epidermal cell-activating agents and one or more antioxidants. The combined employment of the active ingredients enables the enhancement in potency for resisting to the stresses of epidermal cells. When one or more ingredients selected from cholesterol, phytosterol and their derivatives are together used, the skin barrier functions can further effectively be enhanced. <P>COPYRIGHT: (C)2003,JPO

Description

Detailed Description of the Invention

[0001]

TECHNICAL FIELD The present invention relates to a skin barrier function comprising a combination of active ingredients having a specific effect, which are effective in preventing skin disorders induced by stress such as ultraviolet rays and dryness. The present invention relates to a toughening agent, and further to a skin external preparation having an excellent effect of enhancing the skin barrier function.

[0002]

2. Description of the Related Art The epidermal layer is an organ that is in constant contact with the outside world, and is an important cellular tissue that produces the stratum corneum, which is the main skin barrier. Being on the surface of the skin, it is constantly subjected to various stresses such as changes in ultraviolet rays and humidity and changes in temperature. For example, it is known that active oxygen is generated in the skin when exposed to ultraviolet rays, and as a result, rough skin, dryness, inflammation, and even epidermal disorders such as fine lines are caused. Therefore, as a measure against UV damage,
An external preparation for skin has been used in which a substance having an antioxidant effect or an ultraviolet absorbing effect is blended as an active ingredient. On the other hand, regarding antioxidants and ultraviolet absorbers, their safety is being reexamined. Furthermore, in addition to the above-mentioned ultraviolet rays, the epidermis is constantly subjected to various stresses such as changes in humidity and changes in temperature, which cause the same damage as when exposed to ultraviolet rays.

[0003]

However, the above-mentioned antioxidants prevent cell damage by eliminating active oxygen inside and outside cells and by suppressing generation of active oxygen in ultraviolet absorbers. Although effective, it is ineffective at repairing already damaged cells. In addition, in order to improve rough skin, it is considered to add moisturizers such as polyhydric alcohols, water-soluble polymers such as amino acids and acidic mucopolysaccharides, but the effect is temporary and is fundamental. It is not possible to eliminate such obstacles.

Therefore, an object of the present invention is to enhance the barrier function of the epidermis, prevent damage caused by various stresses applied to the skin from the surrounding environment, and further improve the skin barrier function enhancer and skin. To provide an external preparation.

[0005]

[Means for Solving the Problems] In order to solve the above problems, the present inventors have made various studies and selected one or more kinds selected from epidermal cell activators and an antioxidant. It has been found that the resistance of epidermal cells to stress can be effectively increased by using one kind or two or more kinds of active ingredients in combination. By using the skin external preparation containing this skin barrier function improving agent,
The inventors have found that they exert an excellent effect on the improvement of epidermal damage due to the various stresses described above, and have completed the present invention. In addition, the intercellular lipid plays an important role in the barrier function of the skin, but by using cholesterol among the components constituting the intercellular lipid in combination with the skin barrier function-enhancing agent of the present invention, It was also found that the barrier function of the skin is further enhanced. Furthermore, as a result of further studies, it was found that not only cholesterol but also cholesterol derivatives enhance the effect when used in combination with the skin barrier function-improving agent of the present invention.
In addition, by combining extracts of these plants and fungi, the effect of enhancing the skin barrier function, and a technique of being incorporated into a skin external preparation as an active ingredient for enhancing the skin barrier function, and in combination with cholesterol and its derivatives, The technology for strengthening the skin barrier function has not been known at all until now, and is the first finding of the present inventors.

[0006]

BEST MODE FOR CARRYING OUT THE INVENTION As the epidermal cell activator used in the present invention, arnica, turmeric, moss, moss phoenix, hypericum perforatum, gambiroki, koboku, peony, ginkgo, touki, euphorbiaceae, jujube, carrot, chinensis, lizard,
Extracts of plants, crude drugs and fungi, such as velvet mallow, coltsfoot, butterbur, bamboo shoots, peach, willow orchid, can be preferably used. Hereinafter, plants and fungi that can be used as the epidermal cell activator will be described.

Arni ( Arni used in the present invention
ca montana L. ) Is the Asteraceae ( Compo
In the perennial herb belonging to Sitae ), each part of leaves, stems, flowers, roots and the whole plant can be used, but it is preferable to use one or two parts selected from roots and head flowers.

Turmeric used in the present invention ( Curcu
ma domestica Valet. ) Is a perennial plant belonging to the Zingiberaceae family, and can be used for each part of leaves, stems, flowers, fruits, roots, and the whole plant, but it is preferable to use rhizomes. Also,
Turmeric rhizome dried is a kind of crude drug called "turmeric", and such crude drug can also be used.

The moss ( Po) used in the present invention
lytrichum commune Hedw. )
Is a dioecious moss plant belonging to the family Polytriahceae , which can be used for each part of leaves, stems, bolls , spores and the like, but it is preferable to use the whole plant. Also, the closely related Polytric
hum juniperinum Wild. ex
Hedw. ), Moss ( Polytrichum )
formsum Hedw. ) Etc. can be used similarly.

The primula sikkimensis Hoo used in the present invention
k. ) Is a perennial plant belonging to the Primulaceae family, and can be used for each part of leaves, stems, flowers, seeds, roots and the like, but it is preferable to use flowers. Furthermore, Zhou Mont boric Xun as its allied (Pr
imula vittata Bur. et Fra
nch. ) Can be used as well. Further, dried flowers of Ouka Houshun and Joumon Houshun are crude drugs called "Houshunka", and such crude drugs can also be used.

Hypericum perforatum ( Hy used in the present invention
pericum erectum Thunb. Or
Hypericum perforatum L. )
Is a perennial plant belonging to the family Guttiferae , and can be used for each part of leaves, stems, flowers, roots, and the whole plant, but it is preferable to use the whole plant.

Gambir tree ( U
ncaria gambir (Hunt) Roc
b. ) Is a tree belonging to the family Rubiaceae , and can be used for each part of leaves, branches, stems, bark, roots, flowers, fruits, etc., but it is preferable to use leaves and young branches. Further, the dried aqueous extract of leaves and young branches of Gambir tree is a crude drug called “Acenyak”, and such a crude drug can also be used.

The magnolia ( Magn) used in the present invention
olia officinalis Rehd. et
Wils. ) Is a magnolia family ( Magnoliacea)
In the deciduous tree belonging to e ), leaves, branches, xylem, bark, flowers, fruits, roots, root bark and the like can be used, but it is preferable to use bark. The dried bark of Koboku is a kind of crude drug called "Kouboku", and such a crude drug can also be used.

Peony ( Pae) used in the present invention
onia lactiflora Pall. ) Is a perennial belonging to the family Paeoniaceae ,
Each part of leaves, stems, flowers, fruits, roots and the like and whole grass can be used, but it is preferable to use roots. Further, dried peonies roots have been used as a crude drug in the West.

Senkyu ( Cni used in the present invention
"Dium officinale Makino" is a perennial plant belonging to the Umbelliferae family,
Each part of leaves, stems, flowers, fruits, roots and the whole plant can be used, but it is preferable to use rhizomes. Also, dried rhizome of senkyu is a kind of crude drug called "senkyu", and such crude drug can also be used.

Toki ( Angel used in the present invention
ica acutiloba (Sieb. et Z
ucc. ) Kitagawa is a member of the Umbe family ( Umbe ).
As a perennial plant belonging to L. liferrae ), each part of leaves, stems, flowers, fruits, roots and the whole plant can be used, but it is preferable to use roots. Further, dried Touki root is a kind of crude drug called "Touki", and such crude drug can also be used.

Eucommia ulmoides used in the present invention includes insects of the order Moth Lepidoptera and Coleoptera or larvae thereof,
Clavicip family parasitic on the body
Itaceae ) refers to a complex of fungi belonging to Itaceae ) and a crude drug which is a dried product thereof, and fruit bodies, angiosperms and worms can be used, but it is preferable to use all the complexes including worms. In addition, the Eucommia ulmoides most preferably used in the present invention is a larva of the bat family ( Hepialus armorianus O).
ber. ), And the complex formed by Cordyceps sinensis of the family Baccakinae, is a crude drug, “Pleurotus chinensis” (scientific name: CORDYCEPS), but as a fungus that forms Pleurotus cinerea other than Kordaicep sinensis. ( Cordyceps sobol
ifera B .; ) And pupa ( Cordyceps )
militaris Link), Mimitake mushroom ( C
ordyceps nutans Pat. ) And the like can also be used in the present invention.

Jujube ( Zizip) used in the present invention
hus jujuba Mill. ) Is a tree belonging to the family Rhamnaceae , with leaves,
Although various parts such as branches, trunks, bark, roots, flowers and fruits can be used, it is preferable to use fruits. Further, dried jujube fruit is a herbal medicine called "Thaisou", and such herbal medicine can also be used.

The carrot ( Dauc used in the present invention
us carota L. ) Is an aeriaceae ( Umbell
Iferae ) is a perennial herb that can be used for each part of leaves, stems, roots and the like, and the whole plant is preferably used.

Hienso ( Con
solida jacis (L.) Schur. In addition, Delphinium ajacis L. ) Is
A member of the family Ranuncraceae 1
In the annual plant, each part such as leaves, stems, flowers, seeds, roots and the whole plant can be used, but it is preferable to use roots and seeds.

The lizard used in the present invention ( L
ycopodium clavatum L. Or L
ycopodium clavayum L. va
r. Nipponicum nakai) is an evergreen perennial plant belonging to the family Lycopodiaceae , and its roots, stems, leaves, sporangia, spores and the like can be used, but it is preferable to use the whole plant. Further, the dried whole grass is a crude drug called "Shinkinso", and such a crude drug can also be used.

Below the oil mallow ( A
lthea officinalis L. ) Is a perennial plant belonging to the Malvaceae family, with leaves,
Various parts such as stems, flowers, roots and whole plants can be used, but leaves or roots are preferably used.

The coltsfoot ( Tu used in the present invention
ssilago farfara L. ) Is an Asteraceae ( C
ompositae ) is a perennial herb that contains leaves, stems, flowers,
Each site such as roots and whole plants can be used, but it is preferable to use leaves or flowers.

Bukuritake mushroom ( P
oria cocos (Fr.) Wolf) is a basidiomycete that belongs to the family Polyporaceae . Moreover, the dried sclerotium of Bukuritake mushrooms is a crude drug called "Bukryou", and such a crude drug can also be used.

Peach ( Prunus) used in the present invention
persica Batsch or Prunus
persica Batsch var. david
iana Maxim. ) Is the Rosaceae ( Rosacea)
e ) deciduous fruit trees, including leaves, branches, trunks, bark, roots, flowers,
Although various parts such as fruits and seeds can be used, it is preferable to use seeds. In addition, peach seeds are a kind of crude drug called "tonin", and such crude drug can also be used.

Yanagiran ( Cha used in the present invention
maenerion angustifolium
(L.) Scop. Or Epilobium ang
ustifolium L. ) Is a family of Rhododendron ( Ona
graaceae ) is a large perennial plant with leaves, stems,
Each part of flowers, seeds, roots, and the whole plant can be used, but the whole plant is preferably used. Also, dried whole grass is a herbal medicine called "Koukaishi,"
Such crude drugs can also be used.

Yukinoshita ( Sax used in the present invention
ifraga stolonifera Meer
b. ) Is Saxifragacea ( Saxifragacea)
Among the perennials belonging to e ), each part of leaves, stems, flowers, fruits and the like and whole grass can be used, but it is preferable to use the above-ground parts such as leaves and stems.

Antioxidants used in the present invention include apricots, usbasaicin, unshiu mandarin orange, lauren, ononis, cassia, yellowfin, ginger ginger, koihahahaka, kogaeyanagi, shoujo, ginger, horsetail, elderflower, mistletoe, sage, clove. ,
Extracts of plants such as pearl millet, tormentilla, parsley, adlay, safflower, button, mulberry, mannose wax, purple, mugwort and the like can be preferably used. Hereinafter, plants that can be used as an antioxidant will be described.

Apricot ( Prunu) used in the present invention
s armenia L. ) Is the Rosaceae ( Rosa
ceae ), a tree that is a leaf, branch, trunk, bark, root,
Although various parts such as flowers, fruits and seeds can be used, it is preferable to use seeds. Also, apricot seeds are
It is a kind of crude drug called "Kyonin", and such crude drug can also be used.

Usubasaicin ( A used in the present invention
siasarum sieboldii (Miq.)
F. Maekawa) is a family of the family Asteraceae ( Ar
perennial belonging to istrochiaceae ), leaves,
Although various parts such as stems, flowers, fruits, and roots and whole plants can be used, it is preferable to use rhizomes. Also, Keirinsaishin ( Asiasarum), which is closely related to Usubasaishin
heterotropides F. Maeka
wa var. mandshuricum F. Ma
Similar sites in ekawa) can be used. The dried rhizome of Usubasaicin is a kind of crude drug called "Saishin", and such crude drug can also be used.

Citrus unshiu Marcovitc used in the present invention
h) is a tree belonging to the citrus family ( Rutaceae ), which can use each part of leaves, branches, stems, bark, roots, flowers, fruits, seeds, pericarps, etc., but fruits, pericarps, and leaves must be used. Is preferred. Moreover, the dried skin of Unshu mandarin is a kind of crude drug called "Chinpi", and such crude drug can also be used.

Coptis ( Copt) used in the present invention
is Japanica (Thunb.) Maki
no) is Ranunculacea ( Ranunculacea)
Among the perennials belonging to e ), each part such as leaves, stems, flowers, fruits, roots and the whole plant can be used, but the root is preferably used. In addition, the rhizome of Coptis chinensis is a crude drug called "Oren", and such a crude drug can also be used.

[0033] Ononisu used in the present invention (Onon
is spinosa L. ) Is a legume ( Legum)
As a perennial plant belonging to Inosae ), each part of leaves, stems, flowers, roots and the whole plant can be used, but it is preferable to use roots.

Cassia ( Cinna) used in the present invention
momm cassia Presl. ) Is a small tree belonging to the Lauraceae family, with leaves,
Although various parts such as branches, trunks, bark, roots, flowers and fruits can be used, it is preferable to use bark. The dried bark of Cassia is a crude drug called "Keihi", and such crude drug can also be used.

Yellowfin ( Phell) used in the present invention
edron amurense Rupr. )
Is a deciduous tree belonging to the citrus family ( Rutaceae ), and can be used for each part of leaves, branches, stems, bark, roots, flowers, fruits, etc., but it is preferable to use bark. Also, dried bark of yellowfin. It is a crude drug called “Oubaku”, and such crude drug can also be used.

Genoshoko ( G
eranium nepalense Sweet.
var. thumbergii (Sieb. et
Zuccc. ) Kudo) is a family of Gypsophila ( Gera)
As a perennial plant belonging to Niaceae ), each part of leaves, stems, flowers, fruits and the like and whole plants can be used, but it is preferable to use whole plants.

Melissa officinalis ( Melissa officinalis ) used in the present invention
L. ) Is a perennial plant belonging to the Labiatae family ( Labiatae ), and each part of leaves, stems, roots, flowers, and the whole plant can be used, but leaves are preferably used.

Scutellaria ( Sc) used in the present invention
utellaria baicalensis Geo
rgi) is a perennial plant belonging to the Labiatae family ( Labiatae ), and can be used for each part of leaves, stems, flowers, fruits, roots, and the whole plant, but it is preferable to use rhizomes. Also, dried roots of Scutellaria baicalensis is "Ougon".
It is a kind of crude drug called, and such crude drug can also be used.

Dioh ( Rehmannia gluti
nosa (Gaertn.) Libosch. )
Is a Scrophulariaceae
Among the perennials belonging to e ), each part such as leaves, stems, flowers, fruits, roots and the whole plant can be used, but the root is preferably used. Moreover, the dried root of dio is a crude drug called "dio", and such crude drug can also be used.

Ginger used in the present invention ( Zing
iber officinale Rosc. ) Is a perennial plant belonging to the Zingiberaceae family, and can be used for each part of leaves, stems, flowers, fruits, roots, and the whole plant, but it is preferable to use rhizomes. Also,
Dried ginger rhizome is a kind of crude drug called "Ginger", and such crude drug can also be used.

Horsetail ( Equis) used in the present invention
etum arvense L. ) Is a horsetail ( Eq
It is a summer-green perennial plant belonging to Uisetaaceae ), and various parts such as vegetative stems, spores, leaves, sporangia, spores, and twigs and whole plants can be used, but it is preferable to use whole plants. The spores of horsetail are called “Tsukushi” and are used for food, but such “Tsukushi” can also be used.

The Sambucus nigra L. used in the present invention is a perennial plant belonging to the honeysuckle family ( Caprifoliaceae ) and can be used for each part of leaves, stems, flowers, roots, fruits, berries and the like and whole plants. However, it is preferable to use flowers or berries.

The mistletoe ( Viscum album L.) used in the present invention is an evergreen dioecious semi-parasitic shrub belonging to the family Mistletoe ( Loranthaceae ) and has various sites such as leaves, branches, stems, flowers and fruits. It can be used, but there is no distinction between male and female, and it is preferable to use leaves, branches and stems. In addition, the mistletoe ( Viscum album) which is a closely related plant of this mistletoe
L. var. coloratum (Koma
r. ) Ohwi) 's dried foliage is "Sokisei"
It is a kind of crude drug called, and such crude drug can also be used.

The sage used in the present invention ( Salvi
a officinalis L. ) Is a Lamiaceae ( La
Biatae ) is a perennial plant that can be used in all parts of leaves, stems, roots, flowers and the like, and it is preferable to use leaves.

Clove used in the present invention ( Syzy
gium aromaticum (L.) Merri
lt Perry is a family of Myrtacaceae ( Myrtac).
eae ) is a tree that is a leaf, branch, trunk, bark, root, flower,
Although various parts such as fruits can be used, it is preferable to use buds or leaves. Further, dried buds of clove are crude drugs called "clove", and such crude drugs can also be used.

The Calendula officinalis ( C
alendula officinalis L. )
Is an annual or biennial herb belonging to the family Asteraceae ( Compositae ), and can be used for each part of leaves, stems, flowers, roots and the whole plant, but it is preferable to use flowers.

Tormentilla used in the present invention ( Po
tentilla tormentilla Schr
k) is a perennial plant belonging to the family Rosaceae , and can be used for each part such as leaves, stems, flowers, roots, and whole plants, but it is preferable to use roots.

Parsley used in the present invention ( Petro
selinum sativum Hoffman or Petroselinum crispum Mil
l. ) Is a perennial or perennial plant belonging to the family Umbelliferae , and can be used for each part such as leaves, stems, flowers, fruits and roots, but it is preferable to use leaves and roots.

Coix ( Coix) used in the present invention
Lachryma-jobi L. ) Is a Gramineae ( G
As an annual herb belonging to Ramineae ), each part of leaves, stems, flowers, seeds, roots, and the whole plant can be used, but seeds are preferably used. In addition, seeds obtained by removing the seed coat of pearl barley are a kind of crude drug called "Yokuinin", and such crude drug can also be used.

Safflower used in the present invention ( Cart
hamas tinctorius L. ) Is a two-year herb belonging to the family Asteraceae ( Compositae ), and has leaves, stems,
Each site such as flowers and roots and whole plants can be used, but it is preferable to use flowers or whole plants.

Buttons used in the present invention ( Paeon
ia suffruticosa Andr. ) Is a perennial belonging to the family Paeoniaceae ,
Each part of leaves, stems, flowers, fruits, roots and the whole plant can be used, but it is preferable to use root bark. Dried button root bark is a crude drug called "button pie", and such crude drug can also be used.

Morwas ( Morus) used in the present invention
alba L. ) Is a deciduous tree belonging to the Moraceae family, and can be used for each part such as leaves, branches, stems, bark, roots, root bark, flowers and fruits, but it is preferable to use root bark. In addition, dried young branches of mulberry are called "soushi", dried leaves are "soup", dried fruits are "weevil", and root bark is called "sakuhaku", which can also be used.

Mannen wax used in the present invention ( Ro
S. marinus officinalis L. ) Is an evergreen small shrub belonging to the Labiatae family ( Labiatae ),
Although various parts such as leaves, branches, stems, roots, flowers, and fruits can be used, it is preferable to use leaves or flowers.

Murasaki ( Lith used in the present invention
ospermum erythrorizon Si
eb. et Zucc. ) Is the purple family ( Broag
Inaceae ) is a perennial plant that can be used in various parts such as leaves, stems, flowers, seeds, roots, and the whole plant, but it is preferable to use roots. Moreover, the dried roots of purple purple are a kind of crude drug called "shikon", and such crude drug can also be used.

Artemisia ( Artem) used in the present invention
isia princeps Pamp. ) Is a perennial plant belonging to the family Asteraceae ( Compositae ) and has leaves, stems,
Each part of flowers, fruits, roots, and the whole plant can be used, but leaves are preferably used. Also, dried leaves of mugwort are a kind of crude drug called "mugwort", and such crude drugs can be used.

In the present invention, cholesterol, phytosterols and their derivatives can be used together for the purpose of strengthening the skin barrier function. Among them, cholesterol, phytosterols and long chain fatty acid esters can be preferably used as the derivatives. In particular, in addition to cholesterol and phytosterol from the viewpoint of easy availability of raw materials, in the case of cholesterol derivatives, commercially available “YOFCO CLE-ALF (long chain α-hydroxy fatty acid cholesteryl)” and “YOFCO CL” manufactured by Nippon Seika Co., Ltd. are commercially available.
ES (soft lanolin fatty acid cholesteryl) ", Ajinomoto's" Eldew CL-301 (N-lauroyl-L
-Di (glutamic acid di (cholesteryl behenyl octyldodecyl)) ", Nisshin Oil's" Saracos HS (cholesteryl hydroxystearate) "," Saracos C "
S (cholesteryl stearate) "and the like, and the phytosterol derivative is commercially available as" Y
OFCO MAS (macadamia nut oil fatty acid phytosteryl) ", Ajinomoto's" Eldew PS-203 "
(N-lauroyl-L-glutamate di (phytosteryl 2-octyldodecyl)) "" Eldu PS-
304 (N-lauroyl-L-glutamic acid di (phytosteryl behenyl 2-octyldodecyl)) ", phytosteryl isostearate (phytosteryl isostearate) produced by Tama Seika, etc. are preferably used.

Next, the extraction method of the plant, herbal medicine and fungal extract used in the present invention will be described.

In the present invention, the above-mentioned plants, crude drugs and fungi may be used for extraction as they are, but in consideration of extraction efficiency, extraction may be carried out after treatments such as shredding, drying and crushing. preferable. The extraction is performed by immersing it in an extraction solvent.
It may be stirred or homogenized in an extraction solvent in order to improve the extraction efficiency. As the extraction temperature, it is appropriate to set the temperature to about 5 ° C. to a temperature not higher than the boiling point of the extraction solvent. The extraction time varies depending on the type of extraction solvent and the extraction temperature, but it is suitable to be about 4 hours to 14 days.

As the extraction solvent, in addition to water, methanol,
Lower alcohols such as ethanol, propanol and isopropanol, polyhydric alcohols such as 1,3-butylene glycol, propylene glycol, dipropylene glycol and glycerin, ethers such as ethyl ether and propyl ether, esters such as ethyl acetate and butyl acetate. It is possible to use polar organic solvents such as acetone, acetone, and ketones such as ethyl methyl ketone, and one kind or two or more kinds are selected from these and used. Also, physiological saline, phosphate buffer, phosphate buffered saline, alcohol aqueous solution in which urea is dissolved, or the like may be used.

The extracts of the above-mentioned plants, crude drugs and fungi with the above-mentioned solvents can be contained as they are in the external preparation for skin according to the present invention, but the concentrated and dried product can be redissolved in water or a polar solvent. Alternatively, it may be used after purification treatment such as decolorization, deodorization, desalting or the like within a range that does not impair their skin physiological function-improving action, or after fractionation treatment by column chromatography. For storage, it can be used after being purified and then freeze-dried and dissolved in a solvent before use. It can also be used by encapsulating it in vesicles such as liposomes or in microcapsules.

The skin barrier function enhancer in the present invention is
It can be provided by using the above-mentioned epidermal cell activator in combination with an antioxidant. The amount of the skin barrier function-enhancing agent to be added to the external skin preparation is preferably 0.0001 to 5% by weight, and particularly 0.001 to 1% by weight in the epidermal cell activator. In the same way,
01 to 5% by weight is preferable and 0.001 to 1% by weight is particularly preferable.
Is preferred. Within this range, when a skin barrier function-enhancing agent is blended, it is possible to exert higher effects without affecting the temporal stability of the preparation and the active ingredient in the preparation. Further, the epidermal cell activator and the antioxidant can be mixed in any ratio, but from the viewpoint of the effect of enhancing the skin barrier function, the range of 20: 1 to 1:20 is preferable, and 10: 1 to 1: 1. A range of 10 is more preferable.

When cholesterol and its derivatives are used in combination, the total amount of cholesterols is 0.0
It is preferable to blend in the range of 001 to 10% by weight,
Further, it is particularly preferable to blend in the range of 0.001 to 5% by weight. The total amount of the epidermal cell activator and the antioxidant and the compounding ratio of cholesterol and cholesterol derivative are not particularly limited, and they can be compounded in any ratio.

When the skin barrier function-enhancing agent thus prepared is mixed with an external preparation for skin as an active ingredient,
The total blending amount is preferably 0.0003 to 20% by weight, and particularly preferably 0.001 to 10% by weight in terms of effects.

The external preparation for skin according to the present invention can be provided in various dosage forms such as lotions, emulsions, gels, creams, ointments, powders and granules. In addition, skin cosmetics such as lotion, emulsion, cream, beauty essence, and pack,
Makeup base lotion, foundation cosmetics such as makeup base cream, foundation of each dosage form such as emulsion, oil, and solid, makeup cosmetics such as eye color, cheek color, cleansing cream, cleansing lotion, cleansing foam It can also be provided as a skin cleansing agent such as face wash soap and body shampoo, and a hair cosmetic such as hair shampoo, hair rinse and hair treatment.

The external preparation for skin according to the present invention includes oily components, surfactants, moisturizers, pigments, ultraviolet absorbers, fragrances, antibacterial and antifungal agents in addition to the above-mentioned plant, herbal medicine and fungal extracts. It is also possible to include general raw materials for pharmaceuticals and cosmetics such as, and physiologically active ingredients such as dermal fibroblast activator, anti-inflammatory agent, and whitening agent. Further, there is no problem even if the epidermal cell activating agent or the antioxidant other than the present invention is used in combination.

[0066]

[Examples] Next, a method for producing an extract of plants, crude drugs and fungi as an epidermal cell activator and an antioxidant used in Examples, a test for confirming a stress suppressing effect on epidermal cells, and an example as an external preparation for skin. The present invention will be described in more detail by the effectiveness confirmation test, but the technical scope of the present invention is not limited thereto.

<Production Example of Epidermal Cell Activator><Production Method 1> Dried plants or fungi are crushed,
It is immersed in an aqueous solution of 50% by volume of 10% by weight of ethanol for 1 week at room temperature. This is filtered, concentrated and dried under reduced pressure to obtain an extract. The plant or fungal extracts obtained by this production method were referred to as Production Examples 1 to 21. This is shown in Table 1 together with the use site.

[0068]

[Table 1]

<Production Example 22> The above-ground parts of dried carrot are crushed and immersed in 10 times by weight amount of propylene glycol for 1 week at room temperature. This was filtered and set as Production Example 22.

<Production Example 23> The dried whole plant of Boiled Almond is crushed and immersed in 50% by volume of a 50% by volume aqueous solution of 1,3-butylene glycol at 50 ° C for 1 day.
This was filtered and set as Production Example 23.

<Production Example 24> The dried whole plants of Touki are ground and soaked in 10 times by weight of n-hexane at room temperature for 2 weeks. After filtering this, n-hexane was distilled off and the residue was dried under reduced pressure to give Production Example 24.

<Production Example of Antioxidant><Production Method 2> Dried plants are crushed and immersed in 10% by weight of 50% by volume aqueous ethanol solution for 1 week at room temperature. This is filtered, concentrated and dried under reduced pressure to obtain an extract. The plant or fungal extracts obtained by this production method were referred to as Production Examples 25 to 51. This is shown in Table 2 together with the sites used.

[0073]

[Table 2]

<Production Example 52> Dried cassia bark is ground and soaked in 10 parts by weight of purified water for 1 week at room temperature. This was filtered and set as Production Example 52.

<Production Example 53> Dried whole parsley grass is crushed and immersed in 10% by weight of a 50% by volume aqueous solution of 1,3-butylene glycol at 50 ° C for 1 day. This was filtered and set as Production Example 53.

<Production Example 54> The dried whole plant of Calendula officinalis was crushed, and 10-fold amount of n-hexane was added,
Soak for 2 weeks at room temperature. After filtering this, n-hexane was distilled off and the residue was dried under reduced pressure to obtain Production Example 54.

In addition to the production examples other than the above, when a commercially available raw material is available, there is no problem even if it is used.

<Ultraviolet Stress Inhibition Test> Using human epidermal cells, a test for evaluating changes in resistance to ultraviolet rays was conducted. The combination of an epidermal cell activator and an antioxidant as a skin barrier function enhancer is as follows. As an epidermal cell activator, a Japanese laurel extract (Production Example 10), an extract of Astragalus membranaceus (Production Example 18), an extract of Birodoia mallow (Production Example 16), and an antioxidant, a Cassia extract (Production Example 30), a ginger peach (Manufacturing Example 32), a test in which the Sambucus nigra extract (Manufacturing Example 38) was used alone (Comparative Example 1A to Comparative Example 3B) and the combination test shown in Table 3 (Examples 1 to 3) ) Was done.

Normal human epidermal keratinocytes were seeded on a 96-well plate so that 2.0 × 10 ⁴ cells per well were formed. As a seeding medium, a commercially available medium KG-2 (Kurabo) is used. After culturing for 24 hours, the total amount of plant extract is 0.08mg
The medium was exchanged with a dissolved KG-2 medium so that the concentration became / mL, and the cells were further cultured for 24 hours. After that, UVB 150mJ / with a UVB lamp (Toshiba FL 20SE)
cm ² irradiation and further culture for 24 hours. The neutral red reagent (20 μg / mL) was replaced with a dissolved KG-2 medium, and the cells were cultured for 2 hours. After that, the medium is removed and P
The cells were washed with BS (-), 1N hydrochloric acid (30% by volume aqueous ethanol solution) was added, and the cells were thoroughly mixed. afterwards,
The absorbance (turbidity) at 550 nm and 650 nm was measured, and the cell viability was evaluated by the difference between both measured values. The t-test was performed between the results of the experiment without addition of the extract and the effect of suppressing the ultraviolet stress was determined.

[0080]

[Table 3]

As is clear from Table 3, when the epidermal cell activator and the antioxidant are used in combination, the epidermis after the ultraviolet irradiation is used more than when the epidermal cell activator or the antioxidant is used alone. Increased cell viability. In addition, compared with the case where the active ingredient was not added, the survival rate was significantly improved at a risk rate of 5% in Example 1 and Example 2, and the survival rate was improved at a risk rate of 1% in Example 3. That is, it was revealed that the combined use of the epidermal cell activator and the antioxidant enhances the effect of suppressing the ultraviolet stress of epidermal cells more than the case of using each active ingredient alone.

Next, examples of the epidermal cell activator of Production Examples 1 to 24, the antioxidant of Production Examples 25 to 54, cholesterol and a skin barrier function-enhancing agent using cholesterol will be shown.

<Ultraviolet Stress Inhibition Test 2> It is known that UVB exposure destroys the barrier function of the skin. As a phenomenon showing the collapse of the barrier function, an increase in the amount of water evaporation of the skin is considered. Therefore, in order to evaluate the suppression of the collapse of the skin barrier function, a confirmation test of the suppression effect of ultraviolet stress was performed using hairless mice.

[Examples] Skin barrier function enhancer (1) Stearic acid 1.00 (% by weight) (2) Cetanol 1.00 (3) Diisostearyl malate 3.00 (4) Squalane 8.00 ( 5) Cetyl 2-ethylhexanoate 8.00 (6) Polyoxyethylene sorbitan monostearate (20 EO) 1.50 (7) Glycerin monostearate 1.50 (8) Cholesterol derivative Amount (9) 1 wt% aqueous carboxyvinyl polymer solution 15.00 (10) Dipropylene glycol 6.00 (11) 10 wt% L-arginine aqueous solution 1.50 (12) Purified water balance (13) Epidermal cell activator table Amount described in 4 (14) Antioxidant Amount described in Table 4 Manufacturing method: (1) to (8) are heated to 80 ° C. to uniformly dissolve or disintegrate. And, an oil phase. Also, (9),
(10) and (12) are heated to 80 ° C to form an aqueous phase. The oil phase is added to the aqueous phase with stirring to carry out preliminary emulsification, and then (11) is added and uniformly emulsified using a homomixer. After completion of the emulsification, the mixture was cooled and (13) and (14) were added at 45 ° C. to give Examples 4 to 41 (Table 6).
And Table 7). In addition, the amount of (13) of the corresponding Example was doubled, and (14) was replaced with purified water.
Comparative Example 41A (Table 8), and (14) were doubled,
Substituting purified water for (13) was prepared as Comparative Examples 4B to 41B (Table 9). Moreover, what replaced (13) and (14) with purified water, and mix | blended only a cholesterol derivative was prepared as Comparative Example 35C-Comparative Example 41C (Table 1).
0). Also, (8), (13), (1
Control was carried out by substituting purified water for 4). The cholesterol derivatives listed in Table 5 below were used.

[0085]

[Table 4]

[0086]

[Table 5]

[0087]

[Table 6]

[0088]

[Table 7]

[0089]

[Table 8]

[0090]

[Table 9]

[0091]

[Table 10]

Tests were carried out using the above examples, comparative examples and controls.

The test was carried out by grouping 10 hairless mice (6 week old females). 1. On the back of the hairless mouse.
A total of four 0 cm × 2.5 cm rectangular frames were taken, and 100 μL each of the above-mentioned examples, corresponding two types of comparative examples and controls were applied to each frame once a day for 10 days. Note that Comparative Example 32C to Comparative Example 3
As for the 5C sample, these 4 types of samples were regarded as one group. After that, the hairless mouse was exposed to UVB (200 mJ / c
m ² ) was irradiated. Evaporator EP for transepidermal water loss (TEWL) immediately before irradiation and 72 hours after irradiation
-1 (manufactured by ServoMed). The results are shown in Table 11 and Table 12 as a ratio of the average value of the water evaporation amount immediately before irradiation to the average value of the water evaporation amount 72 hours after the irradiation.
Shown in. The ratio value of the control application site was 4.2, and the amount of water evaporated increased 4.2 times after the irradiation of ultraviolet rays.

[0094]

[Table 11]

[0095]

[Table 12]

From Table 11 and Table 12, it is clear that the degree of increase in the amount of water evaporated after ultraviolet irradiation in the group coated with any sample was smaller than that in the control.
In particular, in the example application group, the increase in the water evaporation amount was suppressed even in comparison with the corresponding comparative examples. That is, it was revealed that the barrier function of the skin was strengthened in the example application group as compared with the comparative example application group.

Furthermore, Example 8 and Example 35, Example 17 and Example 36, Example 13 and Example 37, and Example 3 in which the combination of the epidermal cell activator and the antioxidant is the same.
2 and Example 38, Example 10 and Example 39, Example 12
When the results of Example 40 and Example 21 and Example 41 are compared, the results show that, as shown in Table 13, the examples containing a cholesterol derivative have a higher effect of suppressing an increase in water evaporation. Became clear.

[0098]

[Table 13]

Examples of the skin barrier function enhancer are shown below.

[Example 42] Cleansing massage cream (1) Purified water 100 balance (% by weight) (2) 1,3-butylene glycol 7.00 (3) Sucrose fatty acid ester 3.00 (4) N -Sodium stearoyl-L-glutamate 1.00 (5) Carboxyvinyl polymer (1% by weight aqueous solution) 15.00 (6) L-Arginine (10% by weight aqueous solution) 1.50 (7) Paraoxybenzoic acid ester 0.10 (8) Squalane 44.00 (9) Behenyl alcohol 1.50 (10) Lipophilic glyceryl monostearate 1.50 (11) Stearic acid 1.00 (12) Glyceryl triisostearate 1.00 (13) Hardened oil 0.50 (14) Cholesteryl hydroxystearate 1.00 (15) Perfume 0.10 16) Epidermal cell activator (Production Example 2 (turmeric)) 0.05 (17) Epidermal cell activator (Production Example 3 (Usugimosoke)) 0.05 (18) Epidermal cell activator (Production Example 23 (billow oyster) 2.00 (19) Antioxidant (Production Example 28 (Oren)) 0.05 (20) Antioxidant (Production Example 29 (Ononis)) 0.05 (21) Antioxidant (Production Example 52 (Cassia) )) 2.00 (22) Antioxidant (Production Example 32 (Genshosho)) 0.05 Production method: The oil phase components of (8) to (14) are mixed and heated to 70 ° C. On the other hand, the aqueous phase components (1) to (7) are mixed, dissolved and heated to 70 ° C. The oil phase is gradually added to this aqueous phase component to preliminarily emulsify, then uniformly emulsify with a homomixer, and cool at 40 ° C. (15) to (2).
Add 2) and mix.

Example 43 Lotion for Wiping (1) Purified Water Remainder of 100 (% by Weight) (2) Ethanol 8.00 (3) Glycerin 4.00 (4) Polyglyceryl Monolaurate 0.70 ( 5) Sodium citrate 0.05 (6) Citric acid 0.01 (7) Sucrose fatty acid ester 0.04 (8) Paraoxybenzoic acid ester 0.01 (9) Perfume 0.05 (11) Epidermal cell activator (Production Example 10 (Touki)) 0.03 (12) Epidermal cell activator (Production Example 22 (carrot)) 1.50 (13) Epidermal cell activator (Production Example 14 (hienso)) 0.03 (13) Antioxidant (Production Example 28 (Oren)) 0.03 (14) Antioxidant (Production Example 44 (Parsley)) 0.03 Production method: The components (2) to (14) are uniformly dissolved and mixed,
Add (1) and homogenize.

Example 44 Face Wash Foam (1) Myristic Acid 24.30 (% by Weight) (2) Palmitic Acid 3.65 (3) Self-Emulsifying Glycerin Monostearate 3.00 (4) Cholesterol 0.25 (5) Purified water 100 balance (6) Glycerin 17.00 (7) Potassium hydroxide 7.75 (8) Diglycerin 3.00 (9) 1,3-Butylene glycol 1.00 (10) N- Stearoyl-L-glutamate disodium 1.00 (11) Polyglyceryl monolaurate 0.50 (12) Paraoxybenzoate 0.10 (13) Epidermal cell activator (Production Example 5 (Hypericum perforatum)) 0.10 (14) Epidermal cell activator (Production Example 24 (Touki)) 0.10 (15) Epidermal cell activator (Production Example 16 (Billed Aoi)) 0 10 (16) Antioxidant (Production Example 28 (Oren)) 0.10 (17) Antioxidant (Production Example 53 (Parsley)) 1.00 (18) Perfume 0.10 Production Method: (1) to (4) The oil phase component of 1) is mixed, heated to 75 ° C., dispersed and dissolved. On the other hand, the aqueous phase components (5) to (12) are mixed, dissolved and heated to 75 ° C. The above oil phase is gradually added to this aqueous phase component for saponification, followed by cooling and adding (13) to (18) at 40 ° C. and mixing.

[Example 45] Cleansing cream (1) Purified water 100 balance (% by weight) (2) Glycerin 15.80 (3) Sucrose fatty acid ester 5.00 (4) Polyoxyethylene glyceryl isostearate 3 0.00 (5) 1,3-butylene glycol 1.00 (6) Methyl paraoxybenzoate 0.02 (7) Squalane 32.00 (8) Glyceryl tri-2-ethylhexanoate 18.55 (9) Neo dicaprate Pentyl glycol 9.30 (10) Stearic acid 1.00 (11) Jojoba oil 1.00 (12) Beeswax 1.00 (13) Mixed fatty acid triglyceride 1.00 (14) Cholesteryl stearate 0.50 (15) Perfume 0.10 (16) Epidermal cell activator (Production Example 2 (turmeric)) 0.05 (17) Epidermis Cell activating agent (Production Example 15 (Pleurotus mellifera)) 0.05 (18) Epidermal cell activating agent (Production Example 16 (biloud oyster)) 0.05 (19) Antioxidant (Production Example 28 (Oren)) 0.05 (20) Antioxidant (Production Example 29 (Ononis)) 0.05 (21) Antioxidant (Production Example 30 (Cassia)) 0.05 (22) Antioxidant (Production Example 32 (Gennoshoko)) 05 Production method: The oil phase components of (7) to (14) are mixed, heated and dissolved to 70 ° C. On the other hand, the aqueous phase components (1) to (6) are mixed, dissolved and heated to 70 ° C. The oil phase is gradually added to this aqueous phase component to preliminarily emulsify, then uniformly emulsify with a homomixer, and cool at 40 ° C. (15) to (2).
Add 2) and mix.

Example 46 Face Wash (1) Purified Water Remainder of 100 (% by Weight) (2) Glycerin 17.00 (3) Potassium Hydroxide 7.75 (4) Diglycerin 3.00 (5) 1,3-Butylene glycol 1.00 (6) Methyl paraoxybenzoate 0.10 (7) Myristic acid 24.30 (8) Palmitic acid 3.65 (9) Self-emulsifying glyceryl monostearate 3.00 (10) ) Cholesterol 0.15 (11) Maltitol hydroxyalkyl ether 1.00 (12) Coconut oil fatty acid amide propyl betaine solution (30% by weight aqueous solution) 1.00 (13) Epidermal cell activator (Production Example 5 (Hypericum perforatum)) 0.10 (14) Epidermal cell activator (Production Example 10 (Touki)) 0.10 (15) Epidermal cell activator (Production Example 16 (biloud) Oy)) 0.10 (16) Antioxidant (Production Example 28 (Oren)) 0.10 (17) Antioxidant (Production Example 44 (parsley)) 0.10 (18) Perfume 0.20 Production method: ( The oil phase components of 7) to (12) are mixed, heated to 75 ° C., dispersed and dissolved. On the other hand, the water phase components (1) to (6) are mixed, dissolved and heated to 75 ° C. The above oil phase is gradually added to this aqueous phase component for saponification, followed by cooling and adding (13) to (18) at 40 ° C. and mixing.

[Example 47] Lotion (1) Purified water Remainder of 100 (% by weight) (2) Ethanol 10.00 (3) Glycerin 1.50 (4) Sodium citrate 0.09 (5) Citric acid Acid 0.02 (6) Methyl paraoxybenzoate 0.05 (7) Sucrose fatty acid ester 0.04 (8) Perfume 0.02 (9) Epidermal cell activator (Production Example 6 (Gambir tree)) 0.02 ( 10) Epidermal cell activator (Production Example 11 (Astragalus)) 0.02 (11) Epidermal cell activator (Production Example 12 (jujube)) 0.02 (12) Epidermal cell activator (Production Example 19 (peach)) 0.02 (13) Antioxidant (Production Example 31 (Kihada)) 0.02 (14) Antioxidant (Production Example 38 (Elderberry) 0.02 (15) Antioxidant (Production Example 42 (Duckweed) )) .02 Process: (2) to the component (15) mixed and dissolved,
Add (1) and homogenize.

[Example 48] Emulsion (1) Purified water 100 balance (% by weight) (2) Glycerin 3.60 (3) Carboxyvinyl polymer 0.10 (4) N-stearoyl-L-glutamate sodium 0 .24 (5) Methyl paraoxybenzoate 0.10 (6) 1,3-butylene glycol 0.01 (7) N-stearoyl-L-glutamate disodium 0.01 (8) Xanthan gum 0.01 (9) Poly Sodium acrylate 0.01 (10) L-arginine 0.24 (11) Squalane 3.24 (12) Stearic acid 0.72 (13) Cetanol 0.60 (14) Beeswax 0.48 (15) Lipophilic type Glycerin monostearate 0.48 (16) Jojoba oil 0.10 (17) Mixed fatty acid triglyceride 0.10 (1 ) Behenyl alcohol 0.01 (19) Ethanol 4.00 (20) Perfume 0.05 (21) Epidermal cell activator (Production Example 4 (Houshunka)) 0.05 (22) Epidermal cell activator (Production Example 8 (Peonies) )) 0.05 (23) Epidermal cell activator (Production Example 12 (jujube)) 0.05 (24) Epidermal cell activator (Production Example 16 (billow aoi)) 0.05 (25) Epidermal cell activator ( Production Example 18 (Bukuritaketake) 0.05 (26) Epidermal cell activator (Production Example 19 (peach)) 0.05 (27) Antioxidant (Production Example 29 (Ononis)) 0.05 (28) Antioxidant Oxidizing agent (Production Example 31 (Kihada)) 0.05 Production method: Mix the oil phase components (11) to (18) at 75 ° C.
Heat up to disperse and dissolve. On the other hand, the aqueous phase components (1) to (10) are mixed, dissolved and heated to 75 ° C. The oil phase was gradually added to this aqueous phase component to preliminarily emulsify, then uniformly emulsified with a homomixer, and cooled at 40 ° C. (1
9) to (28) are added and mixed.

[Example 49] Oil-in-water emulsified cream (1) Purified water 100 balance (% by weight) (2) 1,3-butylene glycol 10.00 (3) N-stearoyl-L-glutamate sodium 0 .40 (4) Sucrose fatty acid ester 0.40 (5) L-arginine 0.13 (6) Methyl paraoxybenzoate 0.10 (7) Octyldodecyl myristate 7.00 (8) Glycerin 5.00 (9 ) Squalane 4.00 (10) Lipophilic glyceryl monostearate 3.50 (11) Beeswax 3.00 (12) Stearic acid 1.00 (13) Behenyl alcohol 1.00 (14) Palmitic acid 0.50 (15) ) Cholesterol 0.30 (16) Epidermal cell activator (Production Example 6 (Gambir tree)) 0.10 (17) Epidermal cells Activator (Production Example 9 (Senkyu)) 0.10 (18) Epidermal cell activator (Production Example 17 (Fukidanpopo)) 0.10 (19) Epidermal cell activator (Production Example 20 (Yanagiran)) 0.10 ( 20) Epidermal cell activator (Production Example 21 (Yukinoshita)) 0.10 (21) Antioxidant (Production Example 28 (Oren)) 0.10 (22) Antioxidant (Production Example 39 (Mistletoe mistletoe)) 0 .10 Production method: The oil phase components of (7) to (15) are mixed, heated to 75 ° C., dispersed and dissolved. On the other hand, the water phase components (1) to (6) are mixed, dissolved and heated to 75 ° C. The oil phase was gradually added to the aqueous phase component to preliminarily emulsify, then homogenize with a homomixer, and cool at 40 ° C. (16).
~ (22) is added and mixed.

[Example 50] Pack (1) Purified water 100 balance (% by weight) (2) Polyvinyl alcohol 12.50 (3) Ethanol 10.00 (4) Glycerin 5.00 (5) Tri (capryl) Capric acid) glycerin 0.10 (6) polyethylene glycol (average molecular weight 1540) 3.00 (7) sorbitan monolaurate 0.30 (8) fragrance 0.25 (9) sucrose fatty acid ester 0.05 (10) Methyl paraoxybenzoate 0.02 (11) N-lauroyl-L-glutamic acid di (cholesteryl behenyl octyldodecyl) 0.01 (12) Epidermal cell activator (Production Example 8 (peony)) 0.05 (13) Epidermal cell activator (Production Example 12 (jujube)) 0.05 (14) Epidermal cell activator (Production Example 17 (Fukitanpo) )) 0.05 (15) Antioxidant (Production Example 54 (Pinkweed)) 0.05 Production method: The components (2) to (15) are sequentially added to (1), followed by mixing, dissolution and homogenization. To do.

Regarding each example of the present invention, 25 ° C.
When stored for 6 months, no change in state such as coloring, odor, aggregation of contents components, precipitation or deposition, and phase separation was observed.

[0110]

EFFECTS OF THE INVENTION By combining one or more kinds selected from epidermal cell activators and one or more kinds of active ingredients selected from antioxidants, the resistance of epidermal cells to stress can be enhanced. You can Furthermore, by combining one or two or more selected from specific cholesterol, phytosterol and its derivative,
The barrier function of the skin can be effectively enhanced.

─────────────────────────────────────────────────── ─── Continuation of front page (51) Int.Cl. ⁷ identification code FI theme code (reference) A61K 7/00 A61K 7/00 U 7/48 7/48 7/50 7/50 31/575 31/575 35/64 35/64 35/70 35/70 35/78 35/78 A C D F H J K N Q R T U 35/84 35/84 A A61P 17/00 A61P 17/00 17/16 17 / 16 (72) Inventor Akinori Hanano 1-13-6, Minatojima Nakamachi, Chuo-ku, Kobe, Hyogo Noevir Co., Ltd. Kobe Head Office F-term (reference) 4C083 AA071 AA082 AA111 AA112 AA122 AB032 AC022 AC072 AC102 AC122 AC172 AC242 AC302 AC352 AC372 AC422 AC442 AC482 AC582 AC662 AD042 AD092 AD112 AD222 AD352 AD491 AD492 BB47 CC04 CC05 CC07 CC23 DD23 DD31 DD32 EE12 FF01 4C084 AA20 MA63 NA14 ZA892 ZC022 4C086 AA01 DA11 MA63 ZA89 ZB22 AB22 AB32 AB12 AB32 AB12 AB12 AB32 AB12 AB32 AB12 AB32 AB12 AB32 AB12 AB32 AB12 AB32 AB32 AB12 AB32 AB12 34 AB37 AB38 AB40 AB41 AB48 AB51 AB52 AB55 AB57 AB58 AB59 AB62 AB66 AB77 AB81 AD09 BA08 CA03 MA08 MA63 ZA89 ZB22

Claims (5)

[Claims] 1. A skin barrier function-enhancing agent comprising one or more epidermal cell activators and one or more antioxidants. 2. The epidermal cell activator is Arnica, turmeric, moss moss, oukahoushun, iriswort, gambiroki, koboku, peony, ginkgo, ginkgo, euglena, jujube, carrot, hienso, hikagenokazura, biroupo aoi, fuki aoi, fuuki.
The skin barrier function-enhancing agent according to claim 1, which is an extract of a plant, herbal medicine or fungus selected from butterbur mushroom, peach, willow orchid and yukinoshita. 3. The antioxidant is an apricot, anus basaicin, unshiu mandarin orange, oren, ononis, cassia, kihada, genosho, kousuihaka, kogayanagi,
The extract according to claim 1, which is an extract of a plant selected from dio, ginger, horsetail, elderflower, mistletoe, sage, clove, pearl millet, tormentilla, parsley, pearl barley, safflower, button, muwa, mannenrow, purple mulberry, mugwort. Skin barrier function enhancer. 4. The skin barrier function-enhancing agent according to claim 1, which comprises one or more selected from cholesterol, phytosterol and its derivatives. 5. A skin external preparation containing the skin barrier function-enhancing agent according to claim 1 as an active ingredient.